Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine - which designs nanotechnology-based platforms for clinical translation across specialties - developed a ...

YieldMax MRNA Option Income Strategy ETF's distributions have increased alongside MRNA's share price resurgence. See more on MRNY ETF here.

Melanoma, known for its aggressiveness and high mutational burden, presents itself as a prime candidate for neoantigen-targeted immunotherapies. Although ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer ...

CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S.

Moderna does not plan to ‌invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S.

With $30 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), Merck & Co. | The project, which involves Merck, SK Biosciences, Hilleman Laboratories and CDMO IDT ...

Moderna (MRNA) stock hits a 52-week high to extend its YTD rally following back-to-back years of declines. Read more here.

Moderna shares surge 16% to $50 on five-year melanoma vaccine data showing 49% risk reduction. Analysts target $29.93 despite ...

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...